Duchenne muscular dystrophy (DMD) is a severe and progressive neuromuscular disorder that currently lacks a definitive cure. However, continuous advancements in Duchenne muscular dystrophy treatments are bringing renewed hope to patients and families. Ongoing research and development are expanding the Duchenne muscular dystrophy pipeline, introducing innovative therapies that...

Duchenne Muscular Dystrophy is a severe and progressive neuromuscular disorder that currently has no cure. However, advancements in the Duchenne Muscular Dystrophy Therapeutics Market are driving innovation, offering new hope to patients and their families. Researchers and pharmaceutical companies worldwide are actively working to develop groundbreaking therapies aimed at slowing...

Duchenne muscular dystrophy is a rare, progressive neuromuscular disorder caused by mutations in the dystrophin gene. While exon-skipping therapies have significantly shaped the Duchenne muscular dystrophy market, researchers are now actively exploring alternative approaches to enhance treatment outcomes. Current Treatment Options for Duchenne Muscular Dystrophy (DMD) Patients...

  The medical world has taken a revolutionary step forward with the approval of ELEVIDYS, the first gene therapy for treating Duchenne Muscular Dystrophy (DMD). Developed by Sarepta Therapeutics, this innovative treatment targets the underlying cause of DMD, providing hope to countless patients affected by this devastating disorder. This article delves into the FDA approval of ELEVIDYS,...